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Systemiclupuserythematosus(SLE)isanautoimmunediseasewithunknownetiologyaﬀectingmorethanonemillionindividuals
eachyear.ItischaracterizedbyB-andT-cellhyperactivityandbydefectsintheclearanceofapoptoticcellsandimmunecomplexes.
Understanding the complex process involved and the interaction between various cytokines, chemokines, signaling molecules,
and pattern-recognition receptors (PRRs) in the immune pathways will provide valuable information on the development of
novel therapeutic targets for treating SLE. In this paper, we review the immunopathological roles of novel cytokines, chemokines,
signalingmolecules,PRRs,andtheirinteractionsinimmunoregulatorynetworksandsuggesthowtheirdisturbancesmayimplicate
pathological conditions in SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a prototypic systemic
autoimmune disease which is characterized by a loss of toler-
ance to nuclear antigens and various immunological abnor-
malities, including dysregulated activation of both T and B
lymphocytesandsubsequentpolyclonalactivationofcircula-
ting B lymphocytes which produces a large quantity of auto-
reactive antibodies and the formation of immune complexes
causing tissue and organ damage [1]. This is a complex
process involved interaction between various cytokines, che-
mokines, signaling molecules, and pattern-recognition re-
ceptors (PRRs) in the immune pathways. With the advent
of new and advanced technique which include intracellular
cytokine analysis by ﬂow cytometry combined with multi-
plex quantization of cytokine levels in recent years, it had
provided us a reasonable understanding of the activation
proﬁle of cytokine production and new insight in the im-
mune and cellular mechanism in the pathogenesis of SLE,
which further clarify the signiﬁcance of the current body of
literatures. This had provided valuable information on the
development of novel therapeutic targets for treating SLE.
This article will focus on the recent advances of cytokines,
chemokines, signaling molecules, and the role of PRRs in
immunopathogenesis in SLE.
2. Imbalance of Th1/Th2 CytokinesinSLE
Cytokines are a group of small peptides or glycoprotein pro-
duced by a wide variety of cells with molecular weights be-
tween 8 and 30kDa. They had been shown to play an
essential role in modulating the immune response against
foreign or self-antigens. These mediators have been classiﬁed
accordingto their cellular sourceand eﬀectorfunctions, with
the paradigmatic T helper (Th)1 and Th2 cytokine families
best illustrating this division of function. Th1 cells arise in
response to dendritic cells- (DCs-) derived interleukin- (IL-)
12, produce tumor necrosis factor- (TNF-) α, interferon-
(IFN-) γ, and are involved in mediating strong inﬂammatory
responses to intracellular pathogens. IL-4-mediated Th2 cell2 Clinical and Developmental Immunology
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Figure 1: Eﬀector T-cell diﬀerentiation (Th1, Th2, Th17 and TFH), the expression of transcription factors, eﬀector cytokines, chemokine
receptors, and T-cell functions.
diﬀerentiation results in cells that produce cytokines, includ-
ing IL-4, IL-5, and IL-13, which mediate antibody responses
to extracellular pathogens (Figure 1).
The ratios of Th1 and Th2 cytokines have been inves-
tigated to determine the cytokine homeostasis in order to
determine whether Th1 or Th2 predominance during the
development of SLE [2, 3]. SLE was thought to be a Th2-po-
larized disease because of the production of auto-antibod-
ies speciﬁc for self-antigens [4]. However, signiﬁcantly ele-
vated cytokines for Th1 response including IL-12, TNF-α,
and IFN-γ were also found in the plasma of SLE patients
[5–8]. Th1 dominant immune responses have been generally
considered to be pathological in autoimmune disease via the
induction of inﬂammatory reaction. Recently, few cytokines
which had been shown to be of great importance in patho-
genesis of SLE had surfaced with advent of new technology
in detection, which enhances our understanding of their role
in SLE-related immune pathway. These cytokines, including
IL-12,IL-23,IL-18,IL-21,andIL-33,willbediscussedbelow.
2.1. IL-12. IL-12 is a heterodimeric cytokine of 70kDa
comprising covalently linked p40 and p35 subunit which
has been shown to be a central stimulator of Th1-related
proinﬂammatory cytokine that induces IFN-γ in both innate
and adaptive immunity [9, 10]. IL-12 had been suggested to
be associated with progression of severe glomerulonephritis
[11]. Moreover, mRNA levels of p19, p40, and p35 of IL-12
were found to be signiﬁcantly higher in active SLE patients
compared with those patients with inactive disease [12].
Accordingly, serum level of IL-12 was also found to be sig-
niﬁcantly elevated in SLE patients, and it is associated with
the increased level of Th1 cytokine IFN-γ but decreased
level of Th2 cytokine IL-13 [5, 13, 14]. Conversely, another
study reported the decreased ex vivo production of IL-
12 from peripheral blood polymorphonuclear leukocytes
(PMN) stimulated by lipopolysaccharide (LPS) in patients
with active SLE [15] using a diﬀerent ELISA kit. Recently,
the elevated plasma IL-12 concentration has been shown to
exhibit positive correlation with systemic lupus erythemato-
susdiseaseactivityindex(SLEDAI)inSLEpatientswithrenal
impairment, supporting IL-12 could play a pathological
role in the development of autoinﬂammatory response in
SLE patients with severe disease, probably through the
recruitment of the eﬀector leukocytes to the inﬂamed tissue
for orchestrating the immunoresponse at the site of inﬂam-
mation [16].
2.2.IL-23. IL-23isanovelheterodimericcytokinecomposed
of a unique p19 subunit, and a common p40 subunit shared
with IL-12. IL-23 shares similar intracellular signal transduc-
tion molecules with IL-12, therefore both cytokines exhibit
some overlapping function in promoting cellular immunity
[17]. Diﬀerent from IL-12, IL-23 does not promote the
development of IFN-γ-producing Th1 cells, but is crucial
for the expansion of a pathogenic CD4+ T-cell population
characterized by the production of IL-17 and IL-22 [18, 19].
Recent studies had shown that the mRNA levels of IL-23p19
were signiﬁcantly higher in active SLE patients when patients
were stratiﬁed into diﬀerent disease activity groups, thereby
suggesting that IL-23 should play a role in SLE disease ex-
acerbation [12]. Moreover, the likely signiﬁcance of IL-23
in autoinﬂammatory responses was further supported by a
more recent report indicated that Th1 transcription factor
T-bet could upregulate IL-23 receptor expression and the
diﬀerentiation of Th1 and Th17 cells in autoimmunity [20]
(Figure 1). IL-23 has been reported to enhance the IL-17Clinical and Developmental Immunology 3
secretion by peripheral blood mononuclear cells (PBMC)
from healthy subjects [20]. Moreover, the pathogenic Th17
subgroup expresses elevated level of IL-23 receptor via the
activation by T-bet, thereby representing a distinct inﬂam-
matory Th cell lineage for the development of organ-spe-
ciﬁc autoimmune inﬂammation [18, 20–22]. In order to
better elucidate the involvement of IL-23 in the IL-23/IL-17
autoinﬂammatory axis and the immunopathological mech-
anismsoftheactivationofTh17cellsinSLE,Wongetal.have
used IL-23 as an activating agent to demonstrate the direct
involvement of IL-23 in the IL-23/IL17 inﬂammatory axis.
It acts to induce a distinct T-cell activation state that pro-
duces IL-17 as the eﬀector cytokine that promotes the auto-
inﬂammatory responses in SLE [16].
2.3. IL-18. IL-18 was originally identiﬁed as a factor that
enhances IFN-γ production in macrophages, T lymphocytes,
and DCs [23]. Previous studies also reported that the in-
volvement of this Th1-related cytokine in initiating both in-
nate and acquired immune responses [24, 25]. It has been
elucidated that IL-18 along with IL-12 is a potent inducer
of the inﬂammatory mediators by T lymphocytes, causing
severe inﬂammatory disorders in autoimmune diseases such
as rheumatoid arthritis (RA) [26]. In SLE, previous studies
by our group and others have demonstrated the increased
levels of IL-18 in serum/plasma of aﬀected persons, which
positively correlated with disease severity [13, 27–29]. Of
interest is the elevated urinary IL-18 levels that were found
signiﬁcantly increased in patients with established acute tu-
bular necrosis [30] and the increases within 24 hours after
kidney transplantation in patients with delayed allograft
dysfunction [31], suggesting that IL-18 may serve as an pro-
gnostic marker of renal involvement useful to identify pa-
tients at risk of renal failure. Possible pathogenic role of IL-
18 in lupus has been studied in a mouse model of progressive
disease, demonstrating that IL-18 has a multifaceted role in
autoimmune lupus, being apparently involved both in the ef-
fector phases of the late organ damage and, in some organs,
in the initial pathogenic events [32, 33].
2.4.IL-21. IL-21isapleiotropiccytokine,producedbyCD4+
Th cells, that modulates the diﬀerentiation and function of T
cells, B cells, natural killer (NK) cells, and DCs by binding
to the receptor composing of the IL-21 receptor-α (IL-21Rα)
andthecommonγ chain[34,35].Recentstudyhasintimated
that IL-21 can mediate the diﬀerentiation and generation of
follicular helper T cells (TFH)[ 34, 36]( Figure 1). Neverthe-
less, autocrine production of IL-21 from TFH cells can
potentlystimulatethediﬀerentiationofBcellsintoantibody-
forming cells through IL-21R [37]. As a result, dysregulation
of TFH cell function may relate to the pathogenesis of SLE.
IL-21 has been shown to contribute to the development of
autoimmune diseases in diﬀerent animal models of SLE, ex-
perimental autoimmune encephalomyelitis, and RA [35].
The genetic association of IL-21 polymorphisms has also
been demonstrated in SLE [38]. Recent animal study has re-
vealed that elevated production of IL-21, TFH dysfunction
within germinal centers, and aberrant positive selection of
germinal center B cells are required for the production of
autoantibodies and systemic autoimmunity [39, 40].
2.5. IL-33. IL-33, a novel member of the IL-1 cytokine
family [41], has recently been shown to be involved in the
pathogenesis of chronic inﬂammatory disease [42–44]s i m -
ilar to other family members IL-1 and IL-18 [45]. IL-33 is
responsible for the protection against helminth infections
andpreventionofatherosclerosisbypromotingTh2immune
responses [46]. The IL-33 receptor, consisting of ST2 and
IL-1 receptor accessory protein, is also widely expressed,
particularly on Th2 cells and mast cells [47], to mediate im-
portant eﬀector Th2 functions [48]. Although the elevated
ST2 protein in the sera of SLE and other patients with auto-
immune diseases has been reported [49], its causal relation-
ship with disease activity is still unclear. Recently, signif-
icantly elevated serum soluble ST2 (sST2) but not IL-33 has
been detected in SLE patients, and the levels of sST2 were
found to correlate with the disease activity and severity of
thesemedicalconditions. ItthereforesuggestedthatthesST2
level may have a potential role as a surrogate marker of
disease activity [44]. In this study, no correlation was found
between serum IL-33 level and sST2 level, lupus disease ac-
tivity, or speciﬁc organ involvement. In contrast, others
reported that serum IL-33 level was signiﬁcantly increased
in SLE compared with healthy controls (HCs). Increased IL-
33 level was signiﬁcantly associated with thrombocytopenia,
erythrocytopenia, and anti-SSB antibody, suggesting IL-33
may exert biologic eﬀects on erythrocytes and platelets or
their precursors in SLE [43]. In summary, the role of the IL-
33/ST2 system in the pathogenesis of SLE remained unclear.
3.Imbalance of Th1/Th2 Transcription
Factors in SLE
Although the control of the Th1/Th2 imbalance has been
unclear, there is growing evidence to suggest that two major
transcription factors, T-box expressed in T cells (T-bet) and
GATA binding protein 3 (GATA-3), are the determining
factors of T-helper cell diﬀerentiation [50]. T-bet, a Th1-
speciﬁc transcription factor, has been postulated to initiate
Th1 development while inhibiting Th2 cell diﬀerentiation
[51]. GATA-3 is a member of the GATA zinc ﬁnger protein
family, and enhances the development of the Th2 phenotype
while inhibiting Th1 cells [52–54]. Recent study had demon-
strated that the mRNA levels of T-bet and IFN-γ and the
relative expression levels of T-bet/GATA-3 and IFN-γ/IL-4
were signiﬁcantly higher, in contrast to the lower expressions
of GATA-3 and IL-4, in SLE patients [55]. There were also
signiﬁcant correlations in mRNA expression of T-bet with
IFN-γ and of GATA-3 with IL-4. Additionally, the relative
expressions of T-bet/GATA-3 and IFN-γ/IL-4 were found to
correlate with lupus disease activity. Moreover, the elevated
plasma Th1/Th2 cytokine ratio of IL-18/IL-4 was also shown
tocorrelatepositivelywithdiseaseactivityinallSLEpatients,
suggesting the functional activation of peripheral blood
Th1 cells in SLE patients. Thus, previous study provided
us with new insight that ratio of T-bet/GATA-3 expression
is more informative than the level of either transcription4 Clinical and Developmental Immunology
factor alone, which may be disproportionately aﬀected by
the changes in their coexpression in cell populations. The T-
bet/GATA-3 expression ratio not only enhances our under-
standing of Th1/Th2 polarization, it may also serve as a sup-
plementary tool for further assessment of Th1/Th2 status
and development of SLE disease activity (Figure 1).
4. Th17-Mediated Inﬂammation of SLE
Apart from Th1 and Th2 cells, there is a novel subset of IL-
17 producing eﬀector T helper cells, called Th17 cells, whose
dysregulation is thought to participate in the pathogenesis of
SLE [56, 57]. Transforming growth factor (TGF)-β,I L - 6 ,I L -
21, and IL-23 have been implicated for Th17 formation [58,
59].Otherproteinsinvolvedintheirdiﬀerentiationaresignal
transducer and activator of transcription 3 (STAT3) and
the retinoic-acid-receptor-related orphan receptors alpha
(RORα) and gamma (RORγ)[ 58]. Moreover, eﬀector cytok-
ines associated with this cell type are IL-17, IL-21, and IL-22
[60]( Figure 1). We herein highlighted some of the biological
eﬀectsofIL-17implicationforTh17-mediatedinﬂammation
of SLE.
IL-17 is a type I 17-kDa transmembrane protein that
comprises six members and ﬁve receptors mostly produced
by activated T cells [61]. It is a pleiotropic proinﬂammatory
cytokine that enhances T-cell priming and stimulates epi-
thelial, endothelial, and ﬁbroblastic cells to produce multiple
proinﬂammatory mediators, including IL-1, IL-6, TNF-α,
and chemokines [62]. Additionally, IL-17 also exerts its
eﬀects through the recruitment of monocytes and neutro-
phils by increasing the local production of chemokines
(IL-8, monocyte chemoattractant protein-1, growth-related
oncogene protein-α), the facilitation of T-cell inﬁltration
and activation by stimulating the expression of intercellular
adhesion molecule-1 by T cells as well as the ampliﬁcation
of the immune response by inducing the production of IL-6,
prostaglandin E2, granulocyte-macrophage colony-stimulat-
ing factor, and granulocyte colony-stimulating factor [63].
Lastly, this cytokine synergizes with other cytokines, in
particular with IL-1β,T N F - α,a n dI F N - γ [63].
Wong et al. have demonstrated that SLE patients have
higher plasma/serum levels of IL-17 than HCs [13, 16, 56],
which positively associated with SLE disease activity [16].
Accordingly, the frequency of IL-17-producing T cells is in-
creased in peripheral blood of SLE patients [16, 64]. Sig-
niﬁcant levels of IL-17 and IFN-γ were detected in T cells
from SLE patients [64]. Additionally, overproduction of
total immunoglobulin G (IgG), antidouble stranded DNA,
and IL-6 by PBMC of patients with lupus nephritis was
observed upon the stimulation with IL-17 [65], suggesting
a potential role of IL-17 in human lupus progression. On
the other hand, no elevation of IL-17 was found in serum of
cohort of Japanese lupus patients [66]. Most recent evidence
suggested that the ability of regulatory T cells (Tregs)t oe x -
press IFN-γ and IL-17 was impaired in SLE patients, whereas
the proportion of Tregs was similar between SLE patients
and HCs [67]. Additionally, studies in mice support the
concept that IL-17 and Th17 cells may be involved in
the development of lupus nephritis [56, 68]. For instance,
IL-17 was recently found to be critical for the formation of
autoreactive germinal centres in autoimmune BXD2 mice, a
strain that develops a lupus-like syndrome [69]. In a spon-
taneous mouse model of lupus, the New Zealand Black
(NZB) mice, stimulation of splenocytes with nucleosomes as
an autoantigen results in the activation of large numbers of
IL-17-secreting T cells [70]. Upon adoptive transfer to na¨ ıve
recipient mice, IL-23-dependent IL-17 producing CD4+ ef-
fector T-cell subset Th17 can invade the target organ and
promote the development of organ-speciﬁc autoimmune in-
ﬂammation. Consistently, Wong et al. also found that the
proinﬂammatory cytokine IL-23 and IL-12 can promote the
disease severity by activating pathogenic Th1 and Th17 cells
via the induction of downstream Th1 chemokine CXCL10
andinﬂammatorycytokineIL-17inSLE,demonstratingthat
the IL-23/IL-17 axis of inﬂammation and related molecules
may arise as a therapeutic target for treating autoimmune
disease.
5. Chemokines inSLE
Chemokines in itself refer to a group of smaller cytokines
(mass between 8 to 12kDa) with chemotactic properties,
which are classiﬁed into four families according to the loca-
tionofcysteineresidues.The fourchemokine groupsareCC,
C, CXC, and CX3C, where C is a cysteine and X is any amino
acid residue [71]. These small molecules have had well-
deﬁned roles in directing cell migration necessary for the
initiation of T cell immune response, attraction of appropri-
ate eﬀector cells to sites of inﬂammation, and regulation of
diﬀerential recruitment of T helper (Th1 and Th2) lympho-
cytes [72–74]. There has been growing evidence suggesting
that inﬁltration of T lymphocytes and other leucocytes
into the sites of inﬂammation plays a critical role in organ
involvement in SLE [75]. Recent studies have also shown
that chemokines and their receptors are intimately involved
in regulating organ-speciﬁc leucocyte traﬃcking and inﬂam-
mation, suggesting their important roles in the pathophys-
iologyofautoimmunediseasessuchasRA,multiplesclerosis,
and SLE [76–78]. Chemokine CXCL13 in emerging studies
had consolidated the important role of these chemokines
in pathogenesis of SLE. Other chemokines that will be
brieﬂy discussed in this article mainly include CC and CXC
chemokines which had been shown to play some roles in
SLE disease.
5.1. CXCL13. CXCL13/B lymphocyte chemoattractant
(BLC) is a small cytokine belonging to the CXC chemokine
family that is produced by cells in the omentum, peritoneal
macrophages, and DCs [79, 80], which is selectively chem-
otactic for B cells including both the B1 and B2 subsets
by interacting with speciﬁc chemokine receptor CXCR5
[79,81].TheaccumulationofB1cellsintheperitonealcavity
and spleen are responsible for the body cavity immunity and
theproductionofautoantibodyforthedevelopmentofauto-
immune disease in the murine model [79, 82, 83]. Elevated
levels of B1 cells have been documented in patients with
autoimmune disorders such as Sjogren’s syndrome and
RA [84, 85]. Previous studies using murine model of SLEClinical and Developmental Immunology 5
showed that CXCL13 is highly produced by CD11b+ CD11c+
DCs in the target organs including thymus and kidney for
thechemoattractionofB1cellsinto targetorgan[83,86–88].
Therefore, the elevated expression of CXCL13 by myeloid
dendritic cells (mDCs) in the target organs may play a cru-
cial role in breaking the immune tolerance in the thymus
leading to the activation of self-reactive CD4+ Th cells and
the recruitment of autoantibody producing B cells in the de-
velopment of murine lupus [83, 87, 88]. In addition to that,
studies have revealed that CXCL13 can induce the traﬃcking
of distinct CXCR5+ T cells designated as TFH which are
speciﬁcally involved in high-aﬃnity IgG production in ger-
minal centers developed within B-cell follicles of secondary
lymphoid tissues including lymph nodes, spleen, and tonsils
[36, 89–91]. CD4+ TFH cells, located at B-cell follicles,
provide a T helper function to B cells and represents one of
the most numerous and important subsets of eﬀector T cells
in lymphoid tissue [37, 92]. Several studies demonstrated
that B-cell chemokine CXCL13 is ectopically and highly ex-
pressed in thymus and kidney in murine model for SLE.
Studies on humans also demonstrated that serum CXCL13
level was signiﬁcantly elevated in SLE patients and the
elevation correlated signiﬁcantly with SLE disease activity
[93, 94]. As anti-TNF-α treatment was found to be able to
reduce the plasma level of CXCL13 in RA patients [95], it
had been postulated that serum level of CXCL 13 can act as
a disease activity marker for both RA and SLE patients.
5.2. CC Chemokines. Monocyte chemoattractant protein-1
(MCP-1/CCL2) is a prototype CC chemokine, which can
attract monocytes, T cells, NK cells, and basophils [96, 97].
An increase of serum MCP-1/CCL2 was observed with the
progression of disease activity in SLE patients compared to
HCs [98]. Further investigation reported that cerebral spinal
ﬂuids (CSF) MCP-1/CCL2 levels were signiﬁcantly higher in
neuropsychiatric syndromes of systemic lupus erythemato-
sus (NPSLE) patients than those non-NPSLE patients [99].
Regulated upon activation, normal T-cell-expressed and
secreted (RANTES)/CCL5 is another CC chemokine which
attracts monocytes, memory T cells, and NK cells [100]. In-
creased plasma RANTES/CCL5 concentrations were found
in SLE patients more than in controls, and correlated signiﬁ-
cantly with SLEDAI score [101]. Moreover, the expression of
miR-125a was found to contribute to the elevated expression
of RANTES/CCL5 in SLE [102]. In addition to that, studies
from animal models and patients with lupus nephritis dem-
onstrated that inﬂammatory chemokines, especially CCL2
and CCL5, are detectable in kidney tissues and urine before
other signs of inﬂammation [103–106]. With this ﬁnding,
urine chemokines had been proposed as a possibility to
s e r v ea sb i o m a r k e r sf o rr e n a lS L Eﬂ a r e[ 107], suggesting that
the reduced plasma concentration of these circulating che-
mokines in lupus patients with renal involvement may result
from a protein leakage in the urine.
5.3. CXC Chemokines. Interferon-gamma inducible protein-
10(IP-10)/CXCL10andmonokineinducedbygamma-inter-
feron (MIG)/CXCL9, the prototype of the CXC family,
have chemotactic activity mainly for activated Th1 cells and
are involved in the pathogenesis of various Th1-dominant
autoimmune diseases [71, 108]. Their synthesis and expres-
sionfromneutrophils,macrophages,andotherimmunecells
are induced by IFN-γ, and this response is suppressed by
IL-10 and IL-4 [71, 109]. Th1 cells and IFN-γ had been
shown to be important for cell-mediated inﬂammation in
developing autoimmune disease such as SLE [5], thus impli-
cated that these chemokines might have an important role
in pathogenesis of SLE. Furthermore, several studies have
shown that levels of IP-10/CXCL10 and MIG/CXCL9 were
signiﬁcantly elevated in active SLE [98, 110, 111]. Moreover,
Okamoto et al. reported that IP-10/CXCL10 was upregulated
in the central nervous system (CNS) ﬂuid of NPSLE [112,
113], suggesting that IP-10/MCP-1 ratio in CSF is a useful
diagnostic marker of NPSLE [112]. On the other hand, CXC
chemokinesCXCL8andCXCL1arepotentchemoattractants
andactivatorsofTcells,neutrophils,therebyenhancingtheir
proinﬂammatory and proangiogenic activities [114]. They
also stimulate neutrophil degranulation to release reactive
oxygen radicals, thereby inducing an acute inﬂammatory
reaction [115, 116]. They had also been shown to be sig-
niﬁcantly elevated in serum of patient with active lupus, and
the elevation was associated with disease activity [111].
6.IntracellularSignalingPathwaysinSLE
Signal transduction refers to an ordered biochemical process
by which a signal or stimulus is transferred within a single
cell. This cascade begins with binding of extracellular signal-
ing molecules to cell surface receptors, triggering an initial
stimulus that propagated into the cytoplasm. Nowadays, the
most well-known and established signal transduction path-
way that has been identiﬁed is mitogen-activated protein
kinase (MAPK) pathway. MAPKs are serine and threonine
protein kinases that can be activated by phosphorylation
in response to extracellular stimuli, such as mitogens,
growth factors, cytokines, and osmotic stress [117, 118]. Nu-
cleartranslocationofactivatedMAPKscaninduceandtrans-
activate transcription factors including nuclear factor- (NF-)
κBandactivatorprotein1,whichfacilitatethemodulationof
gene transcription in cellular activation, proliferation, apop-
tosis, and the expression of cytokines, chemokines, adhe-
sion molecules, and metalloproteinases [117, 118]. Three
main distinct MAPKs, p42/p44 extracellular signal-regulated
kinase (ERK), c-Jun NH2-terminal protein kinase (JNK),
and p38 MAPK, have been identiﬁed in mammalian cells.
The activation of NF-κB, JNK, and p38 MAPK plays crucial
roles in cytokine-mediated signaling pathways regulating the
release of chemokines and the expression of adhesion mole-
cules of eosinophils and Th cells [119–121]. Activation of
p38 MAPK has been shown to be crucial for B-cell activation
leading to Ig production, and p38 MAPK regulates the pro-
duction of a number of cytokines, including IL-6 that pro-
motes the diﬀerentiation and survival of plasma cells [122].
Moreover, B-cell-activating factor of the TNF family, an
essential factor for B-cell activation and diﬀerentiation, was
regulated through JNK and p38 MAPK [123]. Furthermore,
nuclear factor of activated T cells (NFAT), a downstream6 Clinical and Developmental Immunology
transcription factor of the ERK and JNK pathways, is essen-
tial for T and B lymphocyte activation and diﬀerentiation
[124], and speciﬁc anti-NFAT drug therapy has been shown
to be pharmacologic armamentarium against RA, inﬂamma-
tory arthropathies, and related autoimmune disorders [125].
7. Interaction between Cytokines, Chemokines,
andSignalingMolecules inSLE
As mentioned before, immunopathogenesis of SLE is a com-
plex process that involved the interaction and synergistic
eﬀect of various cytokines, chemokines, and signaling mole-
cules which perpetuate the disease activity in SLE. This
section below will highlight the recent update on the inter-
action between all these agents in promoting the disease ac-
tivity in SLE.
7.1. Role of IL-18 and Chemokines. The potential role of IL-
18 and chemokines in the exacerbation of SLE disease had
been highlighted in a study, which provided valuable infor-
mation on the development of SLE disease markers [111]. In
this study, plasma concentration of CXCL10, CCL5, CXCL9,
CXCL8, CXCL1, and CCL2 was signiﬁcantly elevated in SLE
patients and the elevation was correlated signiﬁcantly with
disease activity. Furthermore, plasma concentration of IL-
18 was found to be correlated positively with production of
CXCL10, CXCL9, CXCL1, and CXCL8 in SLE patients, it was
also shown to be a potent costimulus for the induction of
these chemokine release from activated PBMC as there was
a signiﬁcant increase in ex vivo production of these inﬂam-
matory chemokines when their PBMC were cultured in the
presence of IL-18.
This enhances our knowledge that successful delivery of
the appropriate population of leucocytes to sites of acute in-
ﬂammation will depend on the repertoire of inducible che-
mokines synthesized locally, and the temporal expression of
chemokine receptors on the leucocytes. Meanwhile, the che-
mokineexpressionsareinﬂuencedbyproinﬂammatorycyto-
kines, mainly IL-18, to present in the local environment of
the cells at the time of stimulation. Furthermore, inﬂam-
matory activities of IL-18, together with the induction of
Th1 cytokine IFN-γ and the activation of Th cells, natural
killer cells (NK), and cytotoxic T lymphocytes-inﬂammatory
chemokines, may even enhance the Th1-mediated inﬂam-
matory process, the activation of NK and T cells, and the
migrationofmacrophagesforinitiatingandperpetuatingthe
Th1 immune response in SLE. In summary, the correlation
of raised plasma concentration and ex vivo production of
inﬂammatory chemokines with disease activity, and their
association with IL-18, supports that the chemotaxis of
Th1/Th2 lymphocytes and neutrophils is important in SLE
pathogenesis.
7.2. Role of CXCL13 and IL-21. Ar e c e n ts t u d y[ 93]h a d
shown that CXCL13 and IL-21 may relate with the immuno-
pathogenesis mediated by the function of TFH cells in SLE as
serum level of all these cytokines were found to be signif-
icantly elevated in lupus patient with the increase in
CXCL13concentrationcorrelatedpositivelyandsigniﬁcantly
with SLEDAI score. Furthermore, cell surface expression of
CXCR5 on Th and B cells and IL-21R on B cells was found to
be signiﬁcantly lower in SLE patients, which indicated that
most diﬀerentiated TFH cells migrate out from circulation
into lymphoid organ upon activation during the disease de-
velopment of SLE. This piece of information suggests that
the elevated production of CXCL13, BAFF, and IL-21 may
be associated with the function of TFH for the immu-
nopathogenesis in SLE, and CXCL13 may serve as a potential
disease marker of SLE.
7.3. Role of IL-23, IL-17, IL-18, Th17, and CXCL10. The
pathogenic role of IL-23/IL-17 autoinﬂammatory axis in SLE
h a db e e ne l u c i d a t e di nar e c e n ts t u d y[ 16]. First, parallelly
elevated plasma IL-12, IL-17, and CXCL10 concentrations
exhibited positive correlation with the SLEDAI in their lupus
patients with renal impairment, which supported that these
cytokines cascade could play a pathological role in the devel-
opment of autoinﬂammatory response in SLE patients with
severe disease, through the recruitment of the eﬀector leuko-
cytes into the inﬂamed tissue for orchestrating the immun-
oresponse at the site of inﬂammation. Second, when using
IL-23 as activator, the CD3 and CD28 costimulated PBMC
responded with an aberrant ex vivo production of IL-17,
which provided robust evidence on the direct involvement
of IL-23 in the IL-23/IL-17 inﬂammatory axis, which acts to
induce a distinct T-cell activation state that produces IL-17
as the eﬀector cytokine that promotes the autoinﬂammatory
responses in SLE. Third, ex vivo production of IL-12, IL-23,
andIL-17fromPMBCwassigniﬁcantlyenhancedbythepre-
senceofIL-18whichindicatedthattheexpressionsofinﬂam-
matory cytokines IL-12, IL-23, and IL-17 and activation of
Th17 cells are in part inﬂuenced by proinﬂammatory cyto-
kine IL-18 present in the local environment of the cells
during stimulation. IL-23-mediated activation of IL-17-pro-
ducing Th cells in SLE patients may closely be inﬂuenced
by IL-18 activation, which orchestrates the inﬂammation of
SLE. In conclusion, proinﬂammatory cytokine IL-18 and IL-
12 family cytokines IL-12 and IL-23 can promote the disease
severity by activating pathogenic Th1 and Th17 cells via
the induction of downstream Th1 chemokine CXCL10 and
inﬂammatory cytokine IL-17 in SLE.
7.4. Role of MAPK, IL-18, and CXCL10. As for the roles of
MAPK transduction pathway in pathogenesis of SLE, highly
abnormal ERK and NF-κB activities in T lymphocytes of
lupus patients had been reported [126, 127]. The lyn kinase
deﬁciency in B lymphocytes and decreased ras-MAPK in T
lymphocytes had also been demonstrated in SLE patients
[128–130]. A recent study had further consolidated the facts
that p38 MAPK and JNK are the key signaling molecules
in regulating the inﬂammation-mediated hyperactivity of T
a n dBl y m p h o c y t e si nS L E[ 131]. In this study, the basal ex-
pressions of p38 MAPK in CD4+ Tl y m p h o c y t e s ,C D 8 + T
lymphocytes, and B lymphocytes had been shown to be sig-
niﬁcantly higher in SLE patients, and the expression of
phospho-p38 MAPK in CD4+ Tl y m p h o c y t e s ,C D 8 + Tl y m -
phocytes, and B lymphocytes, and phospho-JNK in CD8+ TClinical and Developmental Immunology 7
lymphocytes and B lymphocytes was also signiﬁcantly ele-
vatedinSLEpatientsupontheactivationbyIL-18,exhibiting
signiﬁcant correlation with the plasma concentrations of
Th1 chemokine CXCL10. Furthermore, the expression of
phospho-JNK in IL-18-activated CD8+ Tl y m p h o c y t e sa n d
the relative percentage (%) fold increase of the expression
of phospho-JNK upon IL-18 activation in B lymphocytes
were signiﬁcantly correlated with SLE disease activity index.
Therefore,theinﬂammation-mediatedactivationofJNKand
p38 MAPK signaling pathways in T and B lymphocytes can
be the underlying intracellular mechanism causing lympho-
cyte hyperactivity in SLE.
8.Pattern-RecognitionReceptors inSLE:
Friend or Foe
An infectious etiology of SLE has been a longstanding hypo-
thesis [132–134] and with the discovery of PRRs in SLE,
the role of bacteria and viruses in the pathogenesis of SLE
has been invigorated. PRRs can alert and activate the innate
immune system through recognizing the conserved mole-
cular patterns to distinguish extrinsic pathogen-associated
molecular patterns (PAMPs) and endogenous danger-asso-
ciated molecular patterns (DAMPs). Several PRRs partic-
ipated in the recognition of viral components, such as geno-
mic DNA and RNA, in a replication-independent way. Ad-
ditionally, cells express intracellular RNA helicases that func-
tionasPRRsofactivelyreplicatingviruses[135].ThesePRRs
are also essential in establishing antiviral immunity by trig-
gering type I interferon responses.
8.1. Toll-Like Receptor in SLE. Being the most studied PRRs,
Toll-like receptors- (TLRs-) mediated intracellular signaling
isacruciallinkbetweeninnateandadaptiveimmunity[136],
which principally sense structurally conserved molecular
motifs called PAMPs for triggering NF-κB, p38 MAPK,
JNK, and the IFN pathways, which results in the translo-
cation of transcription factors, cytokine modulation, and
IFN-stimulated gene regulation leading to inﬂammatory
responses [137]. The stimulation of TLR by PAMPs is an
important prerequisite for the induction of various autoim-
mune diseases [138]. To date, at least 10 human TLRs have
been identiﬁed, and the functions of human TLR1-9 have
been characterized [138, 139]. Cell surface TLRs (TLR-1, 2,
4, 5, and 6) are designed for the engagement of extracellular
pathogens, whereas the intracellular TLRs (TLR-3, 7, 8, and
9) are against intracellular pathogen-derived products [140].
Animal studies of SLE have indicated that TLRs are
important in the pathogenesis of lupus mouse. For instance,
in myeloid diﬀerentiation primary response gene (MyD) 88-
deﬁcient MRL/MpJ-Fas(lpr) (MRL/lpr) mice, both MyD88-
dependent and -independent innate signals were found to
play a crucial role in the development of autoimmune neph-
ritis [141]. Treatment of lupus-prone mice with a dual
inhibitorofTLR-7andTLR-9wasfoundtoleadtothereduc-
tion of autoantibody production and amelioration of disease
symptoms [142]. Lupus-prone mice deﬁcient in TLR-7 also
failed to generate antibodies against RNA-containing anti-
gens such as Smith, which decreased lymphocyte activation
and serum IgG [143]. Conversely, the absence of TLR-9
can exacerbate the disease activity by the activation of lym-
phocytes and plasmacytoid dendritic cells (pDCs), inducing
the subsequent increase of serum IgG and IFN-γ [143].
EmergingevidencerevealedthatTLR-9wasinvolvedinclass-
switching to pathogenic autoantibody production in SLE
[144, 145]. Accordingly, patients with active SLE had been
showntohaveupregulatedexpressionofTLR-9inperipheral
blood memory and plasma B lymphocytes, suggesting that
endogenous nucleic acids released during apoptosis may
stimulate B lymphocytes via TLR-9 and contribute to SLE
pathogenesis [146]. Upregulated expression of TLR-7 and
TLR-9 mRNA, together with IFN-γ mRNA in PBMC, may
also contribute to the pathogenesis of human lupus [147].
Consistently, other study also revealed that PBMCs of SLE
patients with a higher expression of TLRs are more prone
to be activated by diverse TLR ligands when compared to
HCs [147, 148], suggesting that the innate immune response
for extracellular pathogens and self-originated DNA plays
immunopathological roles via TLR activation in SLE.
Recent study by our group found that antagonist-medi-
ated diminished intracellular TLRs might act as potent ac-
tivators of innate immune responses involved in the higher
prevalence of human papillomavirus infection (HPV) in SLE
[149]. TLR antagonist, such as hydroxychloroquine, might
decrease the expression of intracellular TLRs in SLE patients,
thereby increasing the risk of acquiring HPV infection.
Moreover, high-risk HPV infections may play a predominant
role in further downregulating the expression of intracellular
TLR in SLE patients with HPV infection resulting in a high-
er prevalence of persistent infection, suggesting that the
avoidance of stimulation and downregulation of the innate
immune system, which might permit persistence of HPV in
SLE, is evidently part of an immune evasion strategy used by
oncogenic HPV establishing of persistence infection [149].
8.2. Nucleotide-Binding Oligomerization Domain Containing
2i nS L E .In contrast to the well-elucidated membrane-
bound TLRs, cytoplasmic nucleotide binding oligomerisa-
tion domain (NOD) receptors are a new family of PRRs
for the recognition of extracellular PAMPs [150, 151]. Two
NOD-like receptor (NLR) proteins, namely, NOD1 and
NOD2, can participate in the signaling events triggered by
host recognition of speciﬁc motifs of bacterial peptidogly-
cans (PGNs) and, upon activation, induce the production of
proinﬂammatory mediators [150]. NOD1 recognizes prod-
ucts from gram-negative bacteria (diaminopimelic acids),
whereas NOD2 senses muramyl dipeptide (MDP), a pep-
tidoglycan derived peptide from gram-negative as well as
gram-positive bacteria [152]. It has been shown that NLRs
complement and synergize with TLRs in innate immune
responses [153–156]. NLRs are associated with Crohn’s dis-
ease and inﬂammatory arthritis [155–157]. However, the
precise mechanisms by which NOD-mediated recognition of
PGNs in the pathogenesis of inﬂammatory diseases are still
unclear. Apart from the putative link between the genetic
variants of NOD2 and SLE [158–163], little is known about
the expression and function of NOD2 in SLE [164]. Our
recent study demonstrated an overexpression of NOD2 in8 Clinical and Developmental Immunology
monocyte of immunosuppressant na¨ ıve SLE patients with
longer process might lead to activation of PBMCs to produce
proinﬂammatory cytokines, implicating the innate immune
response for extracellular pathogens in immunopathological
mechanisms in SLE [165]. Conversely, immunosuppressive
therapy may downregulate the expression of NOD2 in CD8+
T, monocytes, mDCs, and pDCs in SLE which subsequent-
ly reduce regulatory cytokine IL-10, allowing for an aberrant
inﬂammatory response contributing towards the regulation
of immunopathological mechanisms of SLE, at the expense
of increasing risk of bacterial infection [165]. NOD1 expres-
sion in PBMC subsets of SLE patients and HCs could not be
detected using ﬂow cytometry [165].
Recently, increased prevalence of HPV and tuberculosis
(TB)inSLEhasbeenreportedbyourgroupandothers[166–
169]. Whether the immune evasion strategy, speciﬁc bacte-
ria, or virus could escape PRRs recognition, establishment of
persistent infection in SLE playing a signiﬁcant part in host-
pathogenic interaction need further considerations. Further
elucidation of the infectious process and immune response
against infections and exploration of the eﬃcacy of agonists
as therapeutic tools for eliminating infected cells in SLE will
be worth investigation.
9. Conclusion
The understanding of the immunopathologic mechanisms
of SLE has been gradually evolving with budding studies on
assessing the activation of monocytes, T, and B lymphocytes
upon stimulation of various stimuli and also underlying
intracellular signaling mechanisms. This further enhanced
our current and limited knowledge regarding the cellular
mechanismandpathwayintheimmunopathogenesisofSLE,
which had shed light on developing potential and novel ther-
apies in treating this chronic immunological disorder. Ther-
apeutic inhibitors of the pathways of JNK or p38MAPK [170,
171] and antibodies against IL-21, CXCL13 [172, 173], and
TLR [174, 175] have been shown to exhibit some promis-
ing beneﬁcial eﬀects. Hopefully, with the advent of more ad-
vanced technology and emergence of more studies, our un-
derstanding for this elusive disease can be further strength-
ened in the future.
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